Authors
Latest:
The Power and Potential of Natural Killer Cell Therapies: A New AwakeningNatural killer cells could redefine medicine and offer new hope for cancer, autoimmune diseases, and neurological disorders through advanced CAR-NK therapies.
Latest:
Lawrence R. Lustig, MD, on Evaluating Gene Therapy for the Treatment of Otoferlin-Related Hearing LossThe chair of the Department of Otolaryngology—Head and Neck Surgery at Columbia University College of Physicians discussed the phase 1/2 CHORD clinical trial evaluating DB-OTO.
Latest:
Stella Vnook, PharmD, on Improving Cell Therapy Delivery to Solid Tumors With Core Shell SpherificationThe chief executive officer of Likarda discussed the company’s CSS technology and how it may reduce off-tissue effects.
Latest:
Paul Harmatz, MD, on Harnessing Accelerated Approval for LSDs, Rare Disease Treatment AdvancementsThe pediatric gastroenterologist and professor in residence at University of California at San Francisco discussed challenges in investigating therapies for rare diseases.
Latest:
CAR T as Frontline Therapy for DLBC Lymphoma: Alex Herrera, MDThe hematologist/oncologist from City of Hope discussed the potential for CAR T-cell therapy in earlier lines of treatment for patients with diffuse large B-cell lymphoma.
Latest:
Roberto Giugliani, MD, PhD, on Advantages of Gene Therapy in MPS Type 2The professor of genetics at Federal University of Rio Grande do Sul discussed how RGX-121 has the potential to change the treatment landscape of MPSII.
Latest:
Liso-Cel Approval Expands CAR T-Cell Access in LBCLNilanjan Ghosh, MD, PhD, discussed the impact of liso-cel's approval.
Latest:
Risk Alleles in Age-Related Macular Degeneration: Steffen Schmitz-Valckenberg, MDThe ophthalmologist from John A. Moran Eye Center discussed the close association between disease progression and uncovered risk alleles.
Latest:
Frederick Locke, MD, and Michael Jain, MD, PhD, on Why Some Patients With Lymphoma Do Not Respond to Cellular ImmunotherapyCancerNetwork® was joined by 2 clinicians from Moffitt Cancer Center to discuss why some patients do not respond to CAR T-cell therapy, despite the significant promise of the treatment modality.
Latest:
Marco Davila, MD, PhD, on Investigating Mechanisms of CAR T Resistance in B-cell MalignanciesThe vice chair for cellular therapies at Roswell Park Comprehensive Cancer Center discussed new research from the center presented at the 2023 Tandem Meetings.
Latest:
Chun-Yu Chen, PhD, on Addressing Hemophilia A With CRISPR/Cas9 mRNA LNP Gene EditingThe research scientist at Seattle Children’s Research Institute discussed findings from mouse research he presented at ASGCT’s 2024 conference.
Latest:
CAR T Therapy Yields Remission in Systemic Lupus ErythematosusFive patients with lupus treated with anti-CD19 CAR T-cell therapy are now in remission.
Latest:
Irene Agodoa, MD, on Addressing GVHD Risks in Treating Hematologic MalignanciesThe senior vice president and head of medical affairs at Orca Bio discussed how Orca-T has been developed to lower the risk of graft-versus-host disease.
Latest:
Addressing Unmet Needs in Mantle Cell Lymphoma With CAR T Therapy: Anita Kumar, MDThe medical oncologist from Memorial Sloan Kettering Cancer Center discussed efforts made to address areas of unmet need in mantle cell lymphoma.
Latest:
Achieving Remission in Chronic Lymphocytic Leukemia With CD4+ CAR T-Cells: Jan Joseph Melenhorst, PhDThe translational immunologist and research professor at Perelman School of Medicine, University of Pennsylvania, discussed persistence of CD4+ CAR T-cells in CLL.
Latest:
The Power and Potential of Natural Killer Cell Therapies: A New AwakeningNatural killer cells could redefine medicine and offer new hope for cancer, autoimmune diseases, and neurological disorders through advanced CAR-NK therapies.
Latest:
Treating Endothelial Disease With One Cornea DonorEdward Holland, MD, chief medical advisor, discussed an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.
Latest:
Improving Safety With CAR Engager ProteinsPaul Rennert, president and chief scientific officer of Aleta BioTherapeutics, discussed the company’s research on CAR T therapies.
Latest:
Gene Therapy for Retinal and Neurological DiseasesMagali Taiel, MD, chief medical officer, GenSight Biologics, discussed future research the company plans to pursue.
Latest:
David S. Hong, MD, on the SURPASS Clinical Trial and TCR T-cell Therapy in Solid TumorsHong presented data from the SURPASS clinical trial at the 2022 European Society for Medical Oncology (ESMO) Congress.
Latest:
Swati Naik, MBBS, on Investigating CD123-CAR T Therapy for Relapsed AMLThe assistant member at St. Jude Children’s Research Hospital discussed updated data from a phase 1 study being conducted at the hospital.
Latest:
Analyzing PostCAR Myeloid NeoplasmsMark Hamilton, MD, PhD, a hematology-oncology and BMT cell therapy fellow at Stanford University, discussed implications of his institution’s findings on treatment-related secondary malignancies.
Latest:
Jeffrey Miller, MD, on Emerging Research With Natural Killer CellsThe deputy director of the Masonic Cancer Center discussed trends of presentations from ESMO 2022.
Latest:
Milind Desai, MD, MBA, on Clinically Evaluating MYBPC3–Associated Hypertrophic Cardiomyopathy Gene TherapyThe director of the Center for Hypertrophic Cardiomyopathy at the Cleveland Clinic discussed the design of the MyPeak-1 clinical trial for TN-201 and the associated MyCLIMB natural history study.
Latest:
Zinaida Good, PhD, on Exploring CAR-T Expansion Through Lineage TracingThe instructor at Stanford Institutes of Medicine discussed the key takeaways of her research into the factors that affect CAR-T expansion.
Latest:
Shannon L. Maude, MD, PhD, on Favorable Safety of Tisagenlecleucel in Pediatric B-ALLThe oncologist from Children's Hospital of Philadelphia discussed long-term safety data with tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.
Latest:
Richard Fessler, MD, on OPC1 Improving Quality of Life With Spinal Cord InjuryThe professor of neurosurgery at Rush University Medical School discussed follow-up in the phase 1/2 trial of LCTOPC1 and further research to be done.
Latest:
Piers Blombery, MBBS, PhD, on More ctDNA, MRD Biomarker Use in Blood Cancer for 2024The associate professor at Peter MacCallum Cancer Centre discussed highlights from the 2023 ASH meeting.
Latest:
Applying a Novel Gene Editing Approach to Chronic Hepatitis BPrecision Bio is taking a novel approach to gene editing to deploy a cure for patients with chronic hepatitis B.
